Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Will Assess Its HERVs MAb Temelimab in Covid-19 Patients

Executive Summary

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

You may also be interested in...



Eye Specialist Oculis Launching Four Key Clinical Studies

The CEO of Oculis tells Scrip the Swiss biotech can become a major ophthalmic player and that its lead asset could become the first topical drug treatment for retinal edema.

Novo Nordisk To 'Double Obesity Drug Sales by 2025'

Novo Nordisk at its Q1 update lifted full-year guidance and voiced confidence it can double sales of innovative treatments for obesity by 2025.

Vertex’s ‘Slow Train To Pain’ R&D Rolls On

Vertex is advancing its sodium channel inhibitor VX-548 to mid-stage trials in the second half of the year as a potential treatment for pain after bunionectomy and abdominoplasty procedures.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel